http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2637430-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f3507e7c06e08d66d3832936b248f1c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-493 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-493 |
| filingDate | 2016-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62c5a32c1cc08750d1dce26b678400da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee4a62b980a84014e7badd116c674494 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_219f861fd89cfcbac2c0a54ea4d184dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25a62a00430f5e961d8255c1358b102c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_823bf63e23119e446b6b998920181238 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9300961af3606328e6d07ee551d26aca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_519022c24ce111f6994233717ae8f71f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33ec8c1c57daba1f88a8062f4c1a73d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e08dde5f71d46c5c9662d61e6e4d450 |
| publicationDate | 2017-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2637430-C1 |
| titleOfInvention | Method for selecting tactics of administration of patients with prolactin-secreting pituitary adenoma resistant to conservative treatment based on analysis of individual specificities of cabergoline pharmacodynamics |
| abstract | FIELD: medicine. n SUBSTANCE: using the reversed-phase high-performance liquid chromatography method with detection on a quadrupole tandem mass spectrometer with ionization in electrospray in the positive ion scan mode, after taking the drug at a dose of 0.5 mg, the cabergoline concentration in the patient's blood plasma is determined. With an increase in drug concentration after taking in 240 minutes, the need to continue conservative cabergoline therapy is identified. In the absence of cabergoline concentration growth dynamics in blood, alternative methods of treatment are used. n EFFECT: invention allows to form a personalized approach to the treatment of patients with partially resistant prolactin-secreting adenomas of the pituitary gland, to identify candidate patients as soon as possible to perform operative treatment, to avoid the development of complications due to ineffective therapy. n 2 dwg, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2732251-C1 |
| priorityDate | 2016-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 110.